Stay updated on Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial page.

Latest updates to the Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial page
- Check6 days agoChange Detected- Revision updated from v3.5.0 to v3.5.2. This appears to be a minor software version update with no visible changes to the study details.SummaryDifference0.0%

- Check13 days agoChange DetectedPadua has been replaced with Padova (35128) as the Veneto site name. Padova is now listed as the site location.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedAdded Naples, Italy 80131 to the locations and removed Napoli, Italy 80131 from the locations.SummaryDifference0.0%

- Check34 days agoChange DetectedPage revision updated to v3.5.0, replacing the previous revision v3.4.3.SummaryDifference0.0%

- Check42 days agoChange DetectedThe page now displays Revision: v3.4.3. The previous Revision: v3.4.2 has been removed.SummaryDifference0.0%

- Check70 days agoChange DetectedFallopian tube cancer is now listed as a condition and the Genetic and Rare Diseases Information Center resource is added; the page version updated from v3.4.1 to v3.4.2.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial page.